ALLMedicine™ Acute Bronchospasm Center

May 3rd, 2021 - BACKGROUND Although rare, atrial myxoma is the most common benign cardiac tumor. The recognized triad of presenting symptoms relates to constitutional, embolic, and obstructive effects produced by the tumor. However, the presentation may be non-sp...

Mar 8th, 2021 - Bronchospasm in children is common; however, due to its sudden nature, radiographic correlation is uncommon. We planned a computed tomography (CT) coronary angiogram for a 5-year-old child for evaluation of Kawasaki disease. The child started to d...

Feb 9th, 2020 - Reference Range Theophylline is a methylxanthine, a class of molecule similar to the xanthines caffeine and theobromine found in a normal diet. [1, 2] It has a half-life of 8 hours in a healthy person but decreases to 4-5 hours in people who smoke...

Feb 9th, 2020 - Theophylline is a methylxanthine, a class of molecule similar to the xanthines caffeine and theobromine found in a normal diet.[1, 2] It has a half-life of 8 hours in a healthy person but decreases to 4-5 hours in people who smoke.[3] In the blood...

Nov 27th, 2019 - In asthma, acute bronchospasm is driven by contractile forces of airway smooth muscle (ASM). These forces can be imaged in the cultured ASM cell or assessed in the muscle strip and the tracheal/bronchial ring, but in each case, the ASM is studied ...

NUCALA is indicated for the add-on maintenance treatment of patients 12 years and older with severe asthma with an eosinophilic phenotype. NUCALA is not indicated for the relief of acute bronchospasm or status asthmaticus.

May 31st, 2021 - DULERA is a combination product containing a corticosteroid and a long-acting beta2-adrenergic agonist (LABA) indicated for: Treatment of asthma in patients 5 years of age and older. (1.1) Important Limitation of Use: Not indicated for the relief ...

May 31st, 2021 - ASMANEX HFA is a corticosteroid indicated for: Maintenance treatment of asthma as prophylactic therapy in patients 5 years of age and older. (1.1) Important limitations: Not indicated for the relief of acute bronchospasm. (1.1) ASMANEX® HFA is ind...

May 31st, 2021 - ASMANEX® TWISTHALER ® is indicated for the maintenance treatment of asthma as prophylactic therapy in adult and pediatric patients 4 years of age and older. Limitations of Use ASMANEX TWISTHALER is not indicated for the relief of acute bronchospas...

May 26th, 2021 - BUDESONIDE AND FORMOTEROL FUMARATE DIHYDRATE INHALATION AEROSOL is a combination product containing a corticosteroid and a long-acting beta 2-adrenergic agonist indicated for: Treatment of asthma in patients 6 years of age and older. ( 1.1) Mainte...

May 5th, 2021 - FLOVENT HFA is indicated for the maintenance treatment of asthma as prophylactic therapy in patients aged 4 years and older. Important Limitation of Use Flovent HFA is not indicated for the relief of acute bronchospasm. FLOVENT HFA is an inhaled c...

Oct 4th, 2019 - The Food and Drug Administration has approved a prefilled, single-use autoinjector of benralizumab (Fasenra) for self-administration in adults with eosinophilic asthma, according to a press release from AstraZeneca. Benralizumab is already approve.

Nov 3rd, 2015 - The US Food and Drug Administration (FDA) approved mepolizumab (Nucala, GlaxoSmithKline) for use in combination with other medications for maintenance treatment of severe asthma in patients aged 12 years or older and with an eosinophilic phenotype...

Nov 3rd, 2015 - The US Food and Drug Administration (FDA) approved mepolizumab (Nucala, GlaxoSmithKline) for use in combination with other medications for maintenance treatment of severe asthma in patients aged 12 years or older and with an eosinophilic phenotype...

Aug 1st, 2014 - The FDA approved another once-daily bronchodilator, olodaterol (Striverdi Respimat), for maintenance treatment of chronic obstructive pulmonary disease (COPD). Approved indications for the long-acting beta-adrenergic agonist (LABA) drug included l...

May 3rd, 2005 - Pulmonology Agents Manufacturer: Schering Drug Approval Classification: Original New Drug Application (Approval Date: 3/30/05) Indication:  Asmanex Twisthaler (mometasone furoate) inhaler is indicated for the maintenance treatment of asthma as pro...